USAResearch and clinical trials
Ruxolitinib-based treatment for HLH in children found safe in a small study
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In the USA, children with HLH (hemophagocytic lymphohistiocytosis) were given a treatment that includes ruxolitinib taken by mouth. The drug was given for eight weeks together with cortisone, and sometimes with etoposide. None of the eight children had severe side effects related to the dose. All five newly diagnosed children had a complete response, and all were alive one year later. The two children whose disease had come back died.
What does it mean for patients and families?
The study is very small; larger studies will clarify the drug's place in first-line treatment. HLH treatment is planned at a specialist center.
Source
Scientific paper: HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis. Blood Advances, 2026. DOI: 10.1182/bloodadvances.2026020265 · PubMed 42241708
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hemophagocytic lymphohistiocytosis (HLH)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.